Umoja Biopharma Presents Data on its Synthetic Cytokine Receptor Platform at the International Society for Cell and Gene Therapy Annual Meeting 2022
04 mai 2022 10h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...
Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells
03 mai 2022 08h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, May 03, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...
Umoja Biopharma to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting
02 mai 2022 16h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...
Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting 2022
08 avr. 2022 13h02 HE
|
Umoja Biopharma, Inc.
SEATTLE, April 08, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an oncology company leveraging its proprietary integrated technologies to create next-generation off-the-shelf in vivo (VivoVec)...